The results of currently available randomized, controlled trials (RCTs) were inconclusive in the choice between SDS and DDS. Meta-analyses have shown an increased risk of MI in the DDS group, without identifying the underlying mechanism(s).
We performed a meta-analysis of 12 major (>100 patients) studies of bifurcation DES PCI: 5?RCTs and 7 nonrandomized observational studies, for a total of 6,961 patients. Random-effects models were used to calculate summary risk ratios (RRs). As a primary endpoint, we assessed the RRs and 95 % confidence intervals (CIs) of definite DES thrombosis; death, MI, and target vessel revascularization (TVR) were evaluated as secondary endpoints.
Compared with SDS, DDS had an increased risk of DES thrombosis (RR: 2.31; 95 % CI: 1.33 to 4.03) and MI (RR: 1.86; 95 % CI: 1.34 to 2.60). Mortality (RR: 1.18; 95 % CI: 0.85 to 1.65) and TVR (RR: 1.02; 95 % CI: 0.80 to 1.30) were similar. The RRs of MI and DES thrombosis were associated (p?= 0.040).
In PCI of coronary bifurcations, SDS should be the preferred approach, as DDS is associated with an increased risk of MI, likely driven by DES thrombosis.